Showing Latest Articles
A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small-cell lung cancer
Lung Cancer, 01/10/2008
Bae SH et al. - In a trial to evaluate the efficacy and safety of biweekly irinotecan and cisplatin (IP) in patients with extensive stage disease (ED) small-cell lung cancer (SCLC), it was shown that the combination chemotherapy was well tolerated and effective in patients with ED SCLC
Methods- Patients with previously untreated ED SCLC received intravenous irinotecan at a dose of 60 mg/m2 and cisplatin at a dose of 30 mg/m2 on days 1 and 15 every 4 weeks
- 35 patients were enrolled in this study
- 3 complete responses and 23 partial responses were confirmed, giving an overall response rate of 74.3%
- After a median of 15.1 months, the median time to progression and overall survival were 7.7 and 12.2 months, respectively
- Grade 3/4 neutropenia occurred in 7 patients and grade 3 febrile neutropenia was observed in 1 patient
- Grade 3 diarrhea occurred in 2 patients
